Literature DB >> 16392821

Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors.

Teresa Disingrini1, Mathias Muth, Clelia Dallanoce, Elisabetta Barocelli, Simona Bertoni, Kerstin Kellershohn, Klaus Mohr, Marco De Amici, Ulrike Holzgrabe.   

Abstract

A novel series of muscarinic receptor ligands of the hexamethonio-type was prepared which contained, on one side, the phthalimidopropane or 1,8-naphthalimido-2,2-dimethylpropane moiety typical for subtype selective allosteric antagonists and, on the other, the acetylenic fragment typical for the nonselective orthosteric muscarinic agonists oxotremorine, oxotremorine-M, and related muscarinic agonists. Binding experiments in M(2) receptors using [(3)H]N-methylscopolamine as an orthosteric probe proved an allosteric action of both groups of hybrids, 7a-10a and 8b-10b. The difference in activity between a-group and b-group hybrids corresponded with the activity difference between the allosteric parent compounds. In M(1)-M(3) muscarinic isolated organ preparations, most of the hybrids behaved as subtype selective antagonists. [(35)S]GTPgammaS binding assays using human M(2) receptors overexpressed in CHO cells revealed that a weak intrinsic efficacy was preserved in 8b-10b. Thus, attaching muscarinic allosteric antagonist moieties to orthosteric muscarinic agonists may lead to hybrid compounds in which functions of both components are mixed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16392821     DOI: 10.1021/jm050769s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

Review 1.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Superagonism at G protein-coupled receptors and beyond.

Authors:  R Schrage; A De Min; K Hochheiser; E Kostenis; K Mohr
Journal:  Br J Pharmacol       Date:  2015-10-24       Impact factor: 8.739

Review 3.  Emerging paradigms in GPCR allostery: implications for drug discovery.

Authors:  Denise Wootten; Arthur Christopoulos; Patrick M Sexton
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

4.  Dynamic ligand binding dictates partial agonism at a G protein-coupled receptor.

Authors:  Andreas Bock; Brian Chirinda; Fabian Krebs; Regina Messerer; Julia Bätz; Mathias Muth; Clelia Dallanoce; Dominika Klingenthal; Christian Tränkle; Carsten Hoffmann; Marco De Amici; Ulrike Holzgrabe; Evi Kostenis; Klaus Mohr
Journal:  Nat Chem Biol       Date:  2013-11-10       Impact factor: 15.040

Review 5.  Rational design of dualsteric GPCR ligands: quests and promise.

Authors:  Klaus Mohr; Christian Tränkle; Evi Kostenis; Elisabetta Barocelli; Marco De Amici; Ulrike Holzgrabe
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

Review 6.  Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs.

Authors:  Sang-Min Lee; Jason M Booe; Augen A Pioszak
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

Review 7.  Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

8.  Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor.

Authors:  Peter Keov; Laura López; Shane M Devine; Celine Valant; J Robert Lane; Peter J Scammells; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2014-07-08       Impact factor: 5.157

Review 9.  Muscarinic acetylcholine receptors: novel opportunities for drug development.

Authors:  Andrew C Kruse; Brian K Kobilka; Dinesh Gautam; Patrick M Sexton; Arthur Christopoulos; Jürgen Wess
Journal:  Nat Rev Drug Discov       Date:  2014-06-06       Impact factor: 84.694

10.  Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor.

Authors:  R Schrage; W K Seemann; J Klöckner; C Dallanoce; K Racké; E Kostenis; M De Amici; U Holzgrabe; K Mohr
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.